Brokers Offer Predictions for Moderna FY2026 Earnings

Moderna, Inc. (NASDAQ:MRNA) – Analysts at Brookline Capital Markets upped their FY2026 earnings per share estimates for shares of Moderna in a research report issued on Friday, November 6th. Brookline Capital Markets analyst L. Cann now expects that the company will earn ($5.45) per share for the year, up from their previous forecast of ($6.46). Brookline Capital Markets has a “Buy” rating on the stock. The consensus estimate for Moderna’s current full-year earnings is ($5.69) per share. Brookline Capital Markets also issued estimates for Moderna’s Q4 2026 earnings at ($2.87) EPS, FY2027 earnings at ($2.79) EPS and FY2028 earnings at ($0.16) EPS.

A number of other brokerages also recently issued reports on MRNA. Evercore lifted their price target on shares of Moderna from $50.00 to $80.00 in a research note on Thursday, October 8th. Bank of America raised their price objective on shares of Moderna from $170.00 to $200.00 and gave the company a “neutral” rating in a report on Friday, October 9th. Piper Sandler reaffirmed an “overweight” rating and set a $305.00 price objective (up from $230.00) on shares of Moderna in a research report on Monday. Citigroup reiterated a “sell” rating on shares of Moderna in a research note on Friday, October 23rd. Finally, William Blair lowered Moderna from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 27th. Six equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $113.75.

Moderna Stock Down 6.8%

MRNA stock opened at $250.83 on Wednesday. The company’s 50 day moving average price is $196.68 and its 200 day moving average price is $93.60. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.47 and a current ratio of 3.62. Moderna has a fifty-two week low of $22.28 and a fifty-two week high of $280.80. The firm has a market capitalization of $101.49 billion, a price-to-earnings ratio of -35.33 and a beta of 1.16.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $1.48. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The business had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $890.25 million. During the same quarter last year, the business posted ($0.51) EPS. The business’s quarterly revenue was up 29.2% compared to the same quarter last year.

Insider Buying and Selling

In related news, insider Shannon Klinger sold 3,471 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the completion of the transaction, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 39,145 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the completion of the transaction, the president owned 1,636,565 shares in the company, valued at $361,222,626.80. This represents a 2.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 197,251 shares of company stock worth $33,875,904 over the last 90 days. 10.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of MRNA. BlackRock Inc. acquired a new stake in Moderna during the 2nd quarter worth $2,142,877,000. Theleme Partners LLP purchased a new position in shares of Moderna during the second quarter worth about $564,272,000. Wellington Management Group LLP grew its holdings in shares of Moderna by 4.4% during the second quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock worth $172,384,000 after purchasing an additional 103,977 shares during the last quarter. First Trust Advisors LP grew its holdings in shares of Moderna by 59.3% during the first quarter. First Trust Advisors LP now owns 2,392,693 shares of the company’s stock worth $121,549,000 after purchasing an additional 891,072 shares during the last quarter. Finally, Merck & Co. Inc. acquired a new stake in shares of Moderna during the second quarter worth about $161,642,545. 75.33% of the stock is owned by hedge funds and other institutional investors.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported third-quarter revenue of about $1.3 billion, up 29% year over year and ahead of expectations, and raised its 2026 revenue-growth outlook to 15%–25%. Lower costs and respiratory-vaccine gains also supported the improved outlook. Why is Moderna stock soaring today?
• Positive Sentiment: Investors also have a potential longer-term catalyst in personalized cancer vaccine intismeran. Phase 3 results reportedly showed a 42% reduction in melanoma recurrence or death, and Moderna is targeting an FDA filing by year-end 2026, which could lead to a decision in 2027. Can Moderna’s first cancer therapy win FDA approval in 2027?
• Neutral Sentiment: Moderna is scheduled to present at the Jefferies Global Health Care Conference on November 18. The event could provide updates, but the announcement itself does not change the company’s outlook. Moderna to present at upcoming conference
• Negative Sentiment: Despite the earnings beat, nearly all of Moderna’s revenue still comes from COVID-related products, leaving investors focused on the challenge of building durable sales beyond the pandemic market. That concern may weigh more heavily after the stock’s sharp recent run. Moderna’s Q3 numbers may not be enough to make the stock a buy
• Negative Sentiment: Valuation is another headwind: Goldman Sachs raised its price target but kept a neutral rating, while a separate analysis put fair value well below the prevailing share price. Brookline also made modest reductions to its long-term earnings estimates, despite maintaining a Buy rating.

Moderna Company Profile

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.